The company's Tofacitinb Citrate Tables (5mg) was obtained drug registration certificate (No.: 2023S01222) approved by NMPA on Aug. 01, which was the first anti-rheumatoid arthritis product got Marketing Authorization.

Tofacitinb citrate, a Janus kinase (JAK) inhibitor, is the global first commercial small-molecule targeted drug for the treatment of rheumatoid arthritis. The drug is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.
hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) amounted to 43.62 million RMB in 2019, and more than 300 million RMB in 2021. In 2022, the sales of Tofacitinb citrate tablets (including sustained-release tablets) in the three major terminal public hospitals in China's cities, county-level and townships was about 350 million RMB.

The company's Tofacitinb citrate API has been approved for market in February 2023, the oral preparation with self-produced API enriched the company's product line and improved the company's comprehensive competitiveness!